| scholarly article | Q13442814 |
| P50 | author | Rakesh Sahay | Q38320955 |
| Yashdeep Gupta | Q51281086 | ||
| P2093 | author name string | Sanjay Kalra | |
| P2860 | cites work | Case Reports That Illustrate the Efficacy of SGLT2 Inhibitors in the Type 1 Diabetic Patient | Q35133751 |
| Extreme gestational starvation ketoacidosis: case report and review of pathophysiology | Q35804386 | ||
| Fuel metabolism in starvation | Q36539491 | ||
| The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus | Q37559421 | ||
| Sodium-glucose cotransporter 2 inhibition in type 1 diabetes: simultaneous glucose lowering and renal protection? | Q38246375 | ||
| Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus | Q38439475 | ||
| Sodium glucose transporter 2 (sglt2) inhibitors: Current status in clinical practice | Q41140105 | ||
| Starvation Diabetes, The Reason for the Use of Glucose in the Treatment of Diabetic Acidosis | Q41830009 | ||
| A case of "pseudo-ketoacidosis". | Q41846233 | ||
| Sodium-glucose cotransporter-2 inhibition and the insulin: Glucagon ratio: Unexplored dimensions | Q41959585 | ||
| Observations on the Effect of Various Carbohydrates on the Ketosis of Starvation in Human Subjects | Q42173180 | ||
| Case of ketoacidosis by a sodium-glucose cotransporter 2 inhibitor in a diabetic patient with a low-carbohydrate diet | Q42974009 | ||
| Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study | Q46223922 | ||
| Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. | Q51326175 | ||
| Dopamine blockade inhibits starvation ketosis in man. | Q51645935 | ||
| In vitro hepatic gluconeogenesis during experimental ketosis produced in steers by 1,3-butanediol and phlorizin | Q70676569 | ||
| THE CALORIE DEFICIENCY HYPOTHESIS OF KETOGENESIS TESTED IN MAN | Q78488237 | ||
| Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration | Q85674886 | ||
| Oxidative stress induces claudin-2 nitration in experimental type 1 diabetic nephropathy | Q87670156 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 524-528 | |
| P577 | publication date | 2015-07-01 | |
| P1433 | published in | Indian Journal of Endocrinology and Metabolism | Q15816442 |
| P1476 | title | Sodium glucose transporter 2 (SGLT2) inhibition and ketogenesis | |
| P478 | volume | 19 |
| Q37588842 | A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus |
| Q38658251 | Acid-base and electrolyte disorders associated with the use of antidiabetic drugs. |
| Q28068120 | Adenosine monophosphate-activated protein kinase-based classification of diabetes pharmacotherapy |
| Q39000587 | Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies |
| Q38663903 | Efficacy and safety of canagliflozin in type 2 diabetes mellitus: systematic review of randomized controlled trials. |
| Q41092635 | Euglycemic diabetic ketoacidosis in type 2 diabetes treated with a sodium-glucose cotransporter-2 inhibitor |
| Q48112714 | Euglycemic ketosis in patients with type 2 diabetes on SGLT2-inhibitor therapy-an emerging problem and solutions offered by diabetes technology |
| Q41843269 | Ketoacidosis in diabetic subjects treated with inhibitors of Na(+)-glucose co-transporters type-2: New mechanisms? |
| Q41092793 | L'acidocétose euglycémique dans le diabète de type 2 traité avec un inhibiteur du cotransporteur sodium-glucose de type 2 |
| Q38936746 | Pharmacokinetic and pharmacodynamic drug evaluation of tofogliflozin for the treatment of type 2 diabetes |
| Q30249371 | Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus |
| Q39300071 | Role of sodium glucose cotransporter-2 inhibitors in type I diabetes mellitus |
| Q37588847 | Safe and pragmatic use of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes mellitus: South Asian Federation of Endocrine Societies consensus statement |
| Q41892101 | Sodium glucose transporter 2 inhibition, euglycemic ketosis and bone mineral loss: Refining clinical practices. |
| Q36357997 | Sodium-glucose co-transporter-2 inhibitors and euglycemic ketoacidosis: Wisdom of hindsight. |
| Q38978384 | Sodium-glucose cotransporter 2 inhibition and health benefits: The Robin Hood effect |
Search more.